Neil J. Shah, MBBS, Memorial Sloan Kettering Cancer Center, New York City, NY, talks on the rapidly evolving treatment landscape of renal cell carcinoma (RCC), highlighting HIF1-alpha inhibitors as an up and coming mono- and combination therapy. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.